Travere Therapeutics (TVTX) to Release Earnings on Tuesday

Travere Therapeutics (NASDAQ:TVTX) will issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($1.09) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, August 3rd. The company reported ($1.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.03. The firm had revenue of $59.70 million during the quarter, compared to analyst estimates of $53.93 million. Travere Therapeutics had a negative net margin of 136.00% and a negative return on equity of 273.80%. On average, analysts expect Travere Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $6.97 on Friday. Travere Therapeutics has a 52-week low of $6.35 and a 52-week high of $23.18. The company has a quick ratio of 3.86, a current ratio of 3.99 and a debt-to-equity ratio of 3.23. The firm’s fifty day moving average is $9.77 and its 200 day moving average is $14.19. The company has a market cap of $522.83 million, a price-to-earnings ratio of -1.54 and a beta of 0.55.

Insider Transactions at Travere Therapeutics

In related news, insider Peter Heerma sold 3,091 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $8.25, for a total value of $25,500.75. Following the completion of the sale, the insider now directly owns 80,257 shares of the company’s stock, valued at $662,120.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP William E. Rote sold 1,815 shares of Travere Therapeutics stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $14.71, for a total value of $26,698.65. Following the transaction, the senior vice president now directly owns 61,173 shares in the company, valued at approximately $899,854.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Heerma sold 3,091 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $8.25, for a total value of $25,500.75. Following the completion of the transaction, the insider now directly owns 80,257 shares of the company’s stock, valued at $662,120.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,818 shares of company stock valued at $124,455. 3.75% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently added to or reduced their stakes in TVTX. State Board of Administration of Florida Retirement System grew its position in shares of Travere Therapeutics by 7.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,685 shares of the company’s stock worth $318,000 after buying an additional 1,450 shares during the last quarter. Ensign Peak Advisors Inc acquired a new stake in Travere Therapeutics in the first quarter valued at approximately $286,000. Envestnet Asset Management Inc. grew its holdings in Travere Therapeutics by 13.4% in the first quarter. Envestnet Asset Management Inc. now owns 10,362 shares of the company’s stock worth $267,000 after purchasing an additional 1,224 shares during the last quarter. Seven Eight Capital LP acquired a new position in shares of Travere Therapeutics during the first quarter worth $242,000. Finally, Point72 Middle East FZE purchased a new stake in shares of Travere Therapeutics during the 2nd quarter valued at $206,000.

Wall Street Analysts Forecast Growth

TVTX has been the topic of a number of recent research reports. Evercore ISI decreased their price objective on Travere Therapeutics from $30.00 to $14.00 in a research report on Friday, September 22nd. HC Wainwright lowered their price target on Travere Therapeutics from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 22nd. Bank of America cut their price objective on shares of Travere Therapeutics from $41.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, September 22nd. Piper Sandler lowered their target price on shares of Travere Therapeutics from $19.00 to $10.00 and set a “neutral” rating for the company in a report on Wednesday, October 25th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Travere Therapeutics in a report on Friday, July 21st. They set an “overweight” rating and a $26.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.